Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. Its products target a range of therapeutic solutions, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental cure, proton pump inhibitor, antiprotozoal, antihistamine, antihypertensive drugs, antiparasitic, antilipidemic drugs, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufactu
| Current Price | ₹263.95 |
|---|---|
| Market Cap | ₹315 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Pharmaceutical Contract Manufacturing Services; Pharmaceutical Products; Anti-infective Drugs; Antibiotics; Antifungal Drugs |
| P/E Ratio | 16.2 |
| Beta (1Y) | -0.09 |
Trident Lifeline Limited is trading at ₹263.95, with a market capitalisation of ₹315 Cr.
Trident Lifeline Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Pharmaceutical Contract Manufacturing Services; Pharmaceutical Products; Anti-infective Drugs; Antibiotics; Antifungal Drugs).
Trident Lifeline Limited has a P/E of 16.2.